Akari Therapeutics announced the appointment of Vatnak Vat-Ho as Chief Business Officer, highlighting his oncology business development expertise. Vat-Ho discussed the potential of Akari's novel PH1 payload platform, which targets RNA splicing in cancer cells, and the progress of their lead candidate AKTX-101 toward clinical trials expected by mid-2027. The company aims to leverage Vat-Ho's experience to advance strategic collaborations and investor engagement while developing next-generation antibody drug conjugates with unique mechanisms for cancer treatment.
Akari Therapeutics' recent executive appointment offers context for readers interested in health-sector developments. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 20:11 WIB: out of 150 priced US health-sector stocks, 69 rose and 74 fell. Notable movers include FLNA at USD 0.54 with a 1-day change of +11.96%, INO at USD 1.31 down -10.54%, and TWST at USD 139.55 up +5.62%.
RUM Group Inc. reported a record quarterly revenue of $96.6 million for Q3 2026, a 290% increase year-over-year, surpassing expectations. Despite this, earnings per share were -$0.19, missing the estimate of -$0.11. The company achieved its first pro...
The 2026 Vertex CompOps™ Index reveals that just 16% of enterprises regularly discuss indirect tax at the board level, while 43% only address it when issues arise. Companies with board-level focus on indirect tax are four times less likely to have er...
Richtech Robotics announced its Intelligent Cleaning System at ISSA Show North America 2026, which integrates autonomous cleaning robots with CCTV cameras to enable proactive, targeted cleaning. This system uses real-time data to optimize cleaning ta...
Blue Gold Limited is reducing operating costs and restructuring its balance sheet to address financial obligations and comply with Nasdaq listing requirements. The company is cutting headcount, streamlining operations, and exploring creditor arrangem...
Longevity Health Holdings announced its Board is exploring strategic alternatives for its bio-aesthetic and therapeutic businesses to maximize stakeholder value. Options under consideration include mergers, sales, licensing, or partnerships. This mov...
